Research Topics
| A M FeldmanSummaryAffiliation: Thomas Jefferson University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Advancing the research mission in an academic department: the creation of a center for translational medicineArthur M Feldman
Department of Medicine, Jefferson Medical College, Philadelphia, Pennsylvania, USA
Clin Transl Sci 3:178-81. 2010..The concept of a translational medicine center may be useful for many departments of academic medical centers...
The physician-hospital team: a successful approach to improving care in a large academic medical centerArthur M Feldman
Jefferson Medical College, Department of Medicine, 1025 Walnut Street, Suite 822, Philadelphia, PA 19107, USA
Acad Med 81:35-41. 2006..Development of faculty leadership skills and enhanced physician accountability helped in overcoming the challenges of change...- Clinical characteristics of vesnarinoneArthur M Feldman
Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, PA, USA
Drug Saf 27:1-9. 2004.... - Cost effectiveness of cardiac resynchronization therapy in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trialArthur M Feldman
Department of Medicine, Jefferson Medical College, Philadelphia, Pennsylvania 19107, USA
J Am Coll Cardiol 46:2311-21. 2005.... - Developing strategies to link basic cardiovascular sciences with clinical drug development: another opportunity for translational sciencesA M Feldman
Department of Medicine, Jefferson Medical College, Philadelphia, Pennsylvania, USA
Clin Pharmacol Ther 81:887-92. 2007..Although mouse models may not always represent the physiology of humans, they provide important information that clinical scientists can utilize in designing safe programs for the evaluation of new pharmacologic agents... 
Adenosine receptor subtypes and the heart failure phenotype: translating lessons from mice to manArthur M Feldman
Jefferson Medical College, Department of Medicine, 1025 Walnut Street, Suite 822, Philadelphia, PA 19107, USA
Trans Am Clin Climatol Assoc 122:198-214. 2011....- Enhanced external counterpulsation improves exercise tolerance in patients with chronic heart failureArthur M Feldman
Department of Medicine, Jefferson Medical College, Philadelphia, Pennsylvania, USA
J Am Coll Cardiol 48:1198-205. 2006.... - Use of a wearable defibrillator in terminating tachyarrhythmias in patients at high risk for sudden death: results of the WEARIT/BIROADArthur M Feldman
Department of Medicine, Jefferson Medical College, Philadelphia, Pennsylvania 19107 5083, USA
Pacing Clin Electrophysiol 27:4-9. 2004.... - Restructuring the academic department of internal medicineArthur M Feldman
Department of Medicine of Thomas Jefferson University Medical College, Philadelphia, PA 19107, USA
Am J Med 118:1430-5. 2005 - Effects of vesnarinone on peripheral circulating levels of cytokines and cytokine receptors in patients with heart failure: a report from the Vesnarinone TrialA Deswal
Winters Center for Heart Failure Research, Houston VA Medical Center, Cardiology Section, Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA
Chest 120:453-9. 2001.... - Overexpression of tumor necrosis factor- alpha activates both anti- and pro-apoptotic pathways in the myocardiumT Kubota
Cardiovascular Institute of the UPMC Health System, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
J Mol Cell Cardiol 33:1331-44. 2001..These results suggest that TNF- alpha by itself is not sufficient to induce apoptosis in cardiac myocytes in vivo... - Anti-tumor necrosis factor-alpha antibody limits heart failure in a transgenic modelT Kadokami
Cardiovascular Institute of the University of Pittsburgh Medical Center Health System, Pittsburgh, PA, USA
Circulation 104:1094-7. 2001..CONCLUSIONS: Blockade of TNF-alpha bioactivity by antibody therapy may both preserve cardiac function and partially reverse pathological changes in congestive heart failure... - Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failureB Bozkurt
Winters Center for Heart Failure Research, Department of Medicine, Veterans Administration Medical Center, Houston, TX 77030, USA
Circulation 103:1044-7. 2001.... - Academic cardiology division in the era of managed care. A paradigm for survivalA M Feldman
Department of Medicine, University of Pittsburgh Pa Medical Center 15213, USA
Circulation 95:740-4. 1997..The resulting network provides access to a university cardiologist in most of the surrounding urban and rural counties and will allow us to compete effectively for capitated contracts... - Treatment of patients admitted to the hospital with congestive heart failure: specialty-related disparities in practice patterns and outcomesS E Reis
Department of Medicine, University of Pittsburgh School of Medicine, Pennsylvania, USA
J Am Coll Cardiol 30:733-8. 1997..This study sought to define specialty-related differences in the care and outcome of patients admitted to the hospital with congestive heart failure (CHF)... - A1 adenosine receptor upregulation accompanies decreasing myocardial adenosine levels in mice with left ventricular dysfunctionHajime Funakoshi
Center for Translational Medicine, Department of Medicine, Jefferson Medical College, Philadelphia, PA 19107, USA
Circulation 115:2307-15. 2007..Therefore, we assessed adenosine levels and selective AR expression in transgenic mice with left ventricular systolic dysfunction secondary to overexpression of tumor necrosis factor-alpha (TNF 1.6)... - Gene expression profiling during the transition to failure in TNF-alpha over-expressing mice demonstrates the development of autoimmune myocarditisZhonghua Tang
Department of Medicine, Center for Translational Medicine, Thomas Jefferson University, Suite 813 College Building, 1025 Walnut Street, Philadelphia, PA 19107, USA
J Mol Cell Cardiol 36:515-30. 2004..The autoimmune response occurs concomitantly with cardiac decompensation and may participate in triggering the transition to failure in TNF1.6 mice... - Cardiac S100A1 protein levels determine contractile performance and propensity toward heart failure after myocardial infarctionPatrick Most
Center for Translational Medicine, Department of Medicine, Thomas Jefferson University, Philadelphia, PA 19107, USA
Circulation 114:1258-68. 2006.... - Cardioprotection afforded by NF-kappaB ablation is associated with activation of Akt in mice overexpressing TNF-alphaYoshihiro Higuchi
Center for Translational Medicine, Dept of Medicine, Jefferson Medical College, Philadelphia, PA 19107, USA
Am J Physiol Heart Circ Physiol 290:H590-8. 2006..Thus, while overexpression of TNF-alpha effected a marked Akt inhibition and NF-kappaB activation in mouse hearts, inhibition of NF-kappaB offered salutary benefits mediated at least in part through activation of Akt... - Tumor necrosis factor receptors 1 and 2 differentially regulate survival, cardiac dysfunction, and remodeling in transgenic mice with tumor necrosis factor-alpha-induced cardiomyopathyYoshihiro Higuchi
Center for Translational Medicine, Department of Medicine, Jefferson Medical College, Philadelphia 19107, USA
Circulation 109:1892-7. 2004..Tumor necrosis factor (TNF)-alpha plays a pathophysiological role in heart failure. Although both TNF receptor 1 (TNFR1) and 2 (TNFR2) are present in the heart, comparatively little is known about the role of TNFR2... - Regulated overexpression of the A1-adenosine receptor in mice results in adverse but reversible changes in cardiac morphology and functionHajime Funakoshi
Center for Translational Medicine, Department of Medicine, Jefferson Medical College, Philadelphia, PA 19107, USA
Circulation 114:2240-50. 2006..To evaluate the temporal relationship between AR signaling and cardiac remodeling, we studied the effects of controlled overexpression of the A1-AR using a cardiac-specific and tetracycline-transactivating factor-regulated promoter... - Regulation of in vivo cardiac contractility by phospholemman: role of Na+/Ca2+ exchangeJufang Wang
Division of Nephrology and Center of Translational Medicine, Department of Medicine, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
Am J Physiol Heart Circ Physiol 300:H859-68. 2011..We conclude that under catecholamine stress when [Na(+)](i) is high, PLM minimizes [Na(+)](i) overload by relieving its inhibition of Na(+)-K(+)-ATPase and preserves inotropy by simultaneously inhibiting Na(+)/Ca(2+) exchanger... - Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST)A Deswal
Winters Center for Heart Failure Research, Department of Medicine, Veterans Affairs Medical Center and Baylor College of Medicine, Houston, TX 77030, USA
Circulation 103:2055-9. 2001..CONCLUSIONS: Cytokines and cytokine receptors are independent predictors of mortality in patients with advanced heart failure. Moreover, circulating levels of cytokines are modified by age, sex, and cause of heart failure... - Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathyD M McNamara
Cardiovascular Institute of the University of Pittsburgh Medical Center, Pittsburgh, PA, USA
Circulation 103:2254-9. 2001.... - 17 Beta-estradiol improves survival in male mice with cardiomyopathy induced by cardiac-specific tumor necrosis factor-alpha overexpressionToshiaki Kadokami
Department of Medicine, Jefferson Medical College, Philadelphia, PA 19107, USA
J Interferon Cytokine Res 25:254-60. 2005..05). The cardiac content of TNF-alpha and interleukin-1beta (IL-1beta) was not changed by E2 treatment regardless of the timing of treatment. Thus, E2 exposure prior to puberty can limit the severity of cardiomyopathy in male TNF1.6 mice... - Enhanced external counterpulsation as treatment for chronic angina in patients with left ventricular dysfunction: a report from the International EECP Patient Registry (IEPR)Ozlem Soran
Cardiovascular Institute, UPMC Health System, Pittsburgh, PA, USA
Congest Heart Fail 8:297-302. 2002..Patients with LV dysfunction achieved a less robust reduction in angina than did those without LV dysfunction. For the majority of the patients in the registry, this reduction was maintained at 6 months... - Treating heart failure with enhanced external counterpulsation (EECP): design of the Prospective Evaluation of EECP in Heart Failure (PEECH) trialArthur M Feldman
Department of Medicine, Jefferson Medical College, 1025 Walnut Street, Philadelphia, PA 19607, USA
J Card Fail 11:240-5. 2005.... - Downregulation of matrix metalloproteinases and reduction in collagen damage in the failing human heart after support with left ventricular assist devicesY Y Li
Cardiovascular Institute, Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
Circulation 104:1147-52. 2001..These changes may contribute to the functional recovery and LV plasticity after LVAD support... - Is there any future for tumor necrosis factor antagonists in chronic heart failure?Arthur M Feldman
Department of Medicine, Jefferson Medical College, Room 822, 1025 Walnut Street, Philadelphia, PA 19107, USA
Am J Cardiovasc Drugs 4:11-9. 2004..Thus, appropriately designed clinical trials and newer anticytokine agents may demonstrate benefit... - Effects of cardiac-restricted overexpression of the A(2A) adenosine receptor on adriamycin-induced cardiotoxicityEman A Hamad
Center for Translational Medicine, Dept of Medicine, Jefferson Medical College, 1025 Walnut St, Suite 822 College, Philadelphia, PA 19107, USA
Am J Physiol Heart Circ Physiol 298:H1738-47. 2010..Our data have direct relevance on the clinical use of adenosine agonists or antagonists in the treatment of patients undergoing adriamycin therapy... - Aldosterone synthase promoter polymorphism predicts outcome in African Americans with heart failure: results from the A-HeFT TrialDennis M McNamara
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
J Am Coll Cardiol 48:1277-82. 2006..We sought to evaluate the effect of the aldosterone synthase promoter polymorphism on heart failure outcomes for subjects in the African American Heart Failure Trial (A-HeFT)... - Pharmacogenetics in heart failure: how it will shape the futureEman Hamad
Center for Translational Medicine, Department of Medicine, Jefferson Medical College, 1025 Walnut Street, Philadelphia, PA 19107, USA
Heart Fail Clin 6:1-10. 2010.... - Phospholemman and beta-adrenergic stimulation in the heartJufang Wang
Department of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
Am J Physiol Heart Circ Physiol 298:H807-15. 2010..We conclude that under stressful conditions in which [Na(+)](i) was high, beta-adrenergic agonist-mediated phosphorylation of PLM resulted in time-dependent reduction in inotropy due to relief of inhibition of Na(+)-K(+)-ATPase... - Polymorphisms in adenosine receptor genes are associated with infarct size in patients with ischemic cardiomyopathyZ Tang
Department of Medicine, The Center for Translational Medicine, The Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
Clin Pharmacol Ther 82:435-40. 2007..These results suggest that genetic variants in the adenosine receptor genes may predict the heart's response to ischemia or injury and might also influence an individual's response to adenosine therapy... - The role of anticytokine therapy in heart failure: recent lessons from preclinical and clinical trials?Arthur M Feldman
Department of Medicine, Thomas Jefferson University Medical College, Philadelphia, PA 19107, USA
Med Clin North Am 87:419-40. 2003..It is hoped that the failure of recent studies to demonstrate salutary benefits in patients with class II to IV heart failure will not diminish enthusiasm for the long-term potential of anticytokine therapy... - The balance between pro-apoptotic and anti-apoptotic pathways in the failing myocardiumBrian S McGowan
Thomas Jefferson University, Center for Translational Medicine and Functional Genomics, Philadelphia, PA 19107, USA
Cardiovasc Toxicol 3:191-206. 2003.... - Regulation of cardiac myocyte contractility by phospholemman: Na+/Ca2+ exchange versus Na+ -K+ -ATPaseJianliang Song
Division of Nephrology, Department of Medicine, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
Am J Physiol Heart Circ Physiol 295:H1615-25. 2008..We conclude that at the single-myocyte level, PLM affects cardiac contractility and [Ca(2+)](i) homeostasis primarily by its direct inhibitory effects on Na(+)/Ca(2+) exchange... - Effects of cardiac resynchronization therapy with or without a defibrillator on survival and hospitalizations in patients with New York Heart Association class IV heart failureJoann Lindenfeld
Department of Medicine, University of Colorado Health Sciences Center, 4200 E Ninth Ave, Denver, CO 80262, USA
Circulation 115:204-12. 2007..We sought to examine the outcomes of NYHA class IV patients enrolled in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial to assess the potential benefits of CRT and CRT-D... - Cardiac resynchronization therapy: from creation to evolution--an evidence-based reviewGeorge E Mark
Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA
Congest Heart Fail 13:84-92. 2007..Appropriately identifying patients who will benefit most from CRT and timing the initiation of resynchronization therapy remain areas of intense investigation... - The emerging role of pharmacogenomics in the treatment of patients with heart failureArthur M Feldman
Department of Medicine, Jefferson Medical College, Philadelphia, Pennsylvania 19107, USA
Ann Thorac Surg 76:S2246-53. 2003 - Modified inferior vena caval anastomosis to reduce tricuspid valve regurgitation after heart transplantationDaniel Marelli
Division of Cardiothoracic Surgery, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania 19107, USA
Tex Heart Inst J 34:30-5. 2007..The modified inferior vena caval anastomosis is simple and safe. It eliminates moderate and severe tricuspid valve regurgitation without routine annuloplasty after orthotopic heart transplantation via the bicaval technique... - Enhanced external counterpulsation: mechanism of actionArthur M Feldman
Division of Cardiology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
Clin Cardiol 25:II11-5. 2002..While each of these three hypotheses may help explain the mechanism behind EECP's effects, more clinical studies are required to refine these proposed explanations... - Induced overexpression of Na+/Ca2+ exchanger transgene: altered myocyte contractility, [Ca2+]i transients, SR Ca2+ contents, and action potential durationJufang Wang
Department of Medicine, Division of Nephrology, Center of Translational Medicine, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
Am J Physiol Heart Circ Physiol 297:H590-601. 2009..In addition, heart failure did not occur 3 to 5 wk after NCX1 transgene was induced to be expressed at levels found in diseased hearts... - Low-dose oral enoximone enhances the ability to wean patients with ultra-advanced heart failure from intravenous inotropic support: results of the oral enoximone in intravenous inotrope-dependent subjects trialArthur M Feldman
Department of Medicine, Jefferson Medical College, Philadelphia, PA 19107, USA
Am Heart J 154:861-9. 2007..v.) inotropic support. Chronic parenteral inotropic therapy in UA-HF is costly and requires an indwelling catheter. An effective and safe oral inotrope would have value... - Pharmacologic therapy of chronic heart failureEman Hamad
Jefferson Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania, USA
Am J Cardiovasc Drugs 7:235-48. 2007.... - Controlled and cardiac-restricted overexpression of the arginine vasopressin V1A receptor causes reversible left ventricular dysfunction through Gαq-mediated cell signalingXue Li
Center for Translational Medicine, Department of Medicine, Jefferson Medical College, Philadelphia, PA 19107, USA
Circulation 124:572-81. 2011..To better understand AVP-mediated signaling in the heart, we created a transgenic mouse with controlled overexpression of the V1A receptor... - The rationale and design of the Surgical Treatment for Ischemic Heart Failure (STICH) trialEric J Velazquez
Division of Cardiovascular Medicine, Department of Medicine, Duke University Medical Center, Durham, NC Duke Clinical Research Institute, Durham, NC, USA
J Thorac Cardiovasc Surg 134:1540-7. 2007..Trial data reflect how these therapies were delivered more than 20 years ago and do not indicate the relative benefits of medical therapy versus coronary artery bypass grafting in contemporary practice... - Coxsackievirus B3 induces T regulatory cells, which inhibit cardiomyopathy in tumor necrosis factor-alpha transgenic miceSally A Huber
Department of Pathology, University of Vermont, Colchester 05446, USA
Circ Res 99:1109-16. 2006..H3 virus infection induces high levels of systemic TNF-alpha, whereas H310A1 virus does not. The low TNF-alpha response during H310A1 infections is likely responsible for the T regulatory cell response in these animals... - Impact of cardiac resynchronization therapy on exercise performance, functional capacity, and quality of life in systolic heart failure with QRS prolongation: COMPANION trial sub-studyTeresa De Marco
University of California, San Francisco Medical Center, San Francisco, CA, USA
J Card Fail 14:9-18. 2008.... - Enhanced external counterpulsation improves exercise duration and peak oxygen consumption in older patients with heart failure: a subgroup analysis of the PEECH trialCharles W Abbottsmith
The Ohio Heart and Vascular Center, Cincinnati, OH 45219, USA
Congest Heart Fail 12:307-11. 2006..017). The authors conclude that an older subgroup of PEECH subjects confirms the beneficial effect of EECP in patients with chronic, stable, mild-to-moderate heart failure... - TNF-alpha contributes to endothelial dysfunction by upregulating arginase in ischemia/reperfusion injuryXue Gao
Department of Veterinary Physiology and Pharmacology, Texas A and M University, College Station, TX 77843 4466, USA
Arterioscler Thromb Vasc Biol 27:1269-75. 2007.... - Adenylyl cyclase: a new target for heart failure therapeuticsArthur M Feldman
Circulation 105:1876-8. 2002 - The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Endorsed by the Heart Failure Society ofLeslie T Cooper
J Am Coll Cardiol 50:1914-31. 2007 - Predictors of sudden cardiac death and appropriate shock in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) TrialLeslie A Saxon
Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
Circulation 114:2766-72. 2006..The factors that determine the risk for sudden death or implantable cardioverter defibrillator therapy in patients receiving cardiac resynchronization therapy (CRT) therapies are largely unknown... - Introduction: there is an important need for increased understanding of the pathophysiology of heart failure postinfarction, new treatment strategies, earlier implementation of effective strategies, and more effective use of existing therapiesCarl J Pepine
Division of Cardiovascular Medicine, University of Florida College of Medicine, Gainesville, Florida 32610, USA
Am J Cardiol 97:1F-3F. 2006 - Working group 1: How to increase the output of cardiologistsKenneth Lee Baughman
J Am Coll Cardiol 44:233-7. 2004 - Assessment of infarct size and myocardial function in mice using transesophageal echocardiographyRavi Ramani
University of Pittsburgh, PA 15213, USA
J Am Soc Echocardiogr 17:649-53. 2004..These tools should provide more accurate assessments in preclinical studies of ischemic cardiomyopathy... - Morphological and functional changes in cardiac myocytes isolated from mice overexpressing TNF-alphaAndrzej M Janczewski
Cardiovascular Institute, University of Pittsburgh Health System, Pittsburgh, Pennsylvania 15213, USA
Am J Physiol Heart Circ Physiol 284:H960-9. 2003.... - Plasma levels of TNF-alpha and IL-6 are inversely related to cytochrome P450-dependent drug metabolism in patients with congestive heart failureReginald F Frye
Department of Pharmaceutical Sciences and Pharmacodynamic Research Center, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania 15261, USA
J Card Fail 8:315-9. 2002..CONCLUSIONS: Cytokine-mediated decreases in drug metabolism may contribute to observed variability in drug response and augment the risk of adverse drug effects in CHF patients... - Calcium-dependent arrhythmias in transgenic mice with heart failureBarry London
Cardiovascular Institute, University of Pittsburgh, Pennsylvania 15213, USA
Am J Physiol Heart Circ Physiol 284:H431-41. 2003.... - Overexpression of tumor necrosis factor-alpha increases production of hydroxyl radical in murine myocardiumYoji Machida
Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812 8582, Japan
Am J Physiol Heart Circ Physiol 284:H449-55. 2003..Damaged myocytes, but not infiltrating inflammatory cells, may be the source of ROS in TG... - Enhanced external counterpulsation in patients with heart failure: a multicenter feasibility studyOzlem Soran
Cardiovascular Institute of the University of Pittsburgh Medical Center, Pittsburgh, PA 15213-2582, USA
Congest Heart Fail 8:204-8, 227. 2002..This study suggests that enhanced external counterpulsation is safe and well tolerated in patients with stable heart failure, and that a randomized, controlled study of enhanced external counterpulsation in these patients is warranted... - Disruption of inducible nitric oxide synthase improves beta-adrenergic inotropic responsiveness but not the survival of mice with cytokine-induced cardiomyopathyHajime Funakoshi
Department of Cardiovascular Medicine, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
Circ Res 90:959-65. 2002.... - Involvement of inducible nitric oxide synthase in cardiac dysfunction with tumor necrosis factor-alphaHajime Funakoshi
Department of Cardiovascular Medicine, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan 812 8582
Am J Physiol Heart Circ Physiol 282:H2159-66. 2002..These results indicate that induction of iNOS may play an important role in the pathogenesis of cardiac dysfunction in this mouse model of cytokine-induced cardiomyopathy... - Strain-specific patterns of autonomic nervous system activity and heart failure susceptibility in miceVladimir Shusterman
Cardiovascular Institute, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA
Am J Physiol Heart Circ Physiol 282:H2076-83. 2002..Strain-specific differences should be considered in selecting the strains of mice used for transgenic and gene targeting experiments... - MMP inhibition modulates TNF-alpha transgenic mouse phenotype early in the development of heart failureYun You Li
Cardiovascular Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA
Am J Physiol Heart Circ Physiol 282:H983-9. 2002.... - Inhibition of tumor necrosis factor receptor-1-mediated pathways has beneficial effects in a murine model of postischemic remodelingRavi Ramani
Cardiovascular Institute, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA
Am J Physiol Heart Circ Physiol 287:H1369-77. 2004..002). MMP-2 and TIMP-2 increased similarly in all infarcted groups. These findings suggest that the benefits of TNFR1 ablation might be attributable at least in part to the attenuation of cytokine-mediated imbalances in MMP-TIMP activity... - Cardiac-specific blockade of NF-kappaB in cardiac pathophysiology: differences between acute and chronic stimuli in vivoMaria Brown
Dept. of Pharmacology and Cell Biophysics, 231 Albert Sabin Way, ML0575, Univ. of Cincinnati, Cincinnati, OH 45267-0575, USA
Am J Physiol Heart Circ Physiol 289:H466-76. 2005.... - Blockade of NF-kappaB improves cardiac function and survival without affecting inflammation in TNF-alpha-induced cardiomyopathyNatsumi Kawamura
Department of Cardiovascular Medicine, Kyushu University Graduate School of Medical Sciences, Higashi ku, Fukuoka, Japan
Cardiovasc Res 66:520-9. 2005..In the present study, we assessed the hypothesis that cardiotoxic effects of proinflammatory cytokines are mediated by the activation of NF-kappaB... - Phospholamban gene ablation improves calcium transients but not cardiac function in a heart failure modelAndrzej M Janczewski
Cardiovascular Institute, University of Pittsburgh, 200 Lothrop Street, 1744 1 BST, Pittsburgh, PA 15213, USA
Cardiovasc Res 62:468-80. 2004..These alterations occur in humans and animals with heart failure, including the TNF1.6 mouse model, in which heart failure arises from cardiac-specific overexpression of tumor necrosis factor alpha (TNF alpha)... - Rationale and design of the enoximone clinical trials programBrian D Lowes
University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
J Card Fail 11:659-69. 2005.... - Atrial contractile dysfunction, fibrosis, and arrhythmias in a mouse model of cardiomyopathy secondary to cardiac-specific overexpression of tumor necrosis factor-{alpha}Samir Saba
Cardiovascular Institute, University of Pittsburgh, 200 Lothrop St, Scaife S572, Pittsburgh, PA 15213, USA
Am J Physiol Heart Circ Physiol 289:H1456-67. 2005..Thus abnormalities in action potential propagation and Ca(2+) handling contribute to the initiation of atrial arrhythmias in this mouse model of heart failure... - Selective disruption of MMP-2 gene exacerbates myocardial inflammation and dysfunction in mice with cytokine-induced cardiomyopathyHidenori Matsusaka
Dept of Cardiovascular Medicine, Kyushu Imoversotu Graduate School of Medical Sciences, Fukuoka, Japan
Am J Physiol Heart Circ Physiol 289:H1858-64. 2005..MMP-2 may play a cardioprotective role in the pathogenesis of cytokine-induced cardiomyopathy... - Mode of death in advanced heart failure: the Comparison of Medical, Pacing, and Defibrillation Therapies in Heart Failure (COMPANION) trialPeter Carson
Division of Cardiology, Veterans Affairs Medical Center, Washington, DC 20422, USA
J Am Coll Cardiol 46:2329-34. 2005.... - Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failureDennis M McNamara
Cardiovascular Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15213, USA
J Am Coll Cardiol 44:2019-26. 2004..We evaluated the interaction of angiotensin-converting enzyme (ACE) inhibitor therapy with the effect of the ACE D/I polymorphism on heart failure survival... - Myocardial expression of fas and recovery of left ventricular function in patients with recent-onset cardiomyopathyRichard Sheppard
McGill University, Sir Mortimer B. Davis-Jewish General Hospital, Montreal, Canada
J Am Coll Cardiol 46:1036-42. 2005..Apoptosis limits myocardial recovery, and represents a potential target for therapeutic intervention... - ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 GuideliSharon Ann Hunt
Circulation 112:e154-235. 2005 - Implantable cardioverter defibrillators and cardiac resynchronization therapy in patients with left ventricular dysfunction: randomized trial evidence through 2004Sana M Al-Khatib
The Duke Clinical Research Institute, Durham, NC 27715, USA
Am Heart J 149:1020-34. 2005..This document summarizes the evidence reviewed at that meeting and the discussions of that evidence... - Selective versus nonselective beta-blockade for heart failure therapy: are there lessons to be learned from the COMET trial?Michael R Bristow
Division of Cardiology, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
J Card Fail 9:444-53. 2003.... - Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failureMichael R Bristow
Division of Cardiology, University of Colorado Health Sciences Center, Denver, CO 80262, USA
N Engl J Med 350:2140-50. 2004.... - The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology Endorsed by the Heart Failure Society of Leslie T Cooper
American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231, USA
Eur Heart J 28:3076-93. 2007
Research Grants
- STICH TRIAL - NEUROHORMONAL/ CYTOKINE/ GENETIC CORE LABArthur Feldman; Fiscal Year: 2006..abstract_text> ..
- STICH TRIAL - NEUROHORMONAL/ CYTOKINE/ GENETIC CORE LABArthur Feldman; Fiscal Year: 2007..Low expression of ACE gene or high levels of adenosine) will be most likely to achieve long-term benefit from either CABG or CABG with SVR. ..